With equity markets reeling due to President Donald Trump's tariffs, many investors are taking this opportunity to buy shares ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

Fintel reports that on April 10, 2025, Mizuho initiated coverage of Tandem Diabetes Care (NasdaqGM:TNDM) with a Neutral ...

Sei Investments Co. lifted its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 305.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The ...

Participants were randomly split into two groups: one used the t:slim X2 insulin pump with Control-IQ+ technology and a Dexcom G6 CGM sensor (AID group), while the other group continued with their ...

The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the ...

Patients were randomly assigned in a 2:1 ratio to either the AID group, which received the t:slim X2 insulin pump with Control-IQ+ technology and a Dexcom G6 sensor, or the control group ...

Control-IQ+ is compatible with both the t:slim X2 insulin pump and Tandem Mobi System. It is available for people with type 1 diabetes (ages 2 years and older) and adults with type 2 diabetes.

The Control-IQ+ algorithm enables AID in conjunction with Tandem’s t:slim X2 and Mobi insulin pumps and a compatible continuous glucose monitor (CGM). The updated algorithm allows for a wider ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with type 2 diabetes using an automated ...